2 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Withdrawn 2 |
Follow Pleural Diseases: new trials by email Literature Review of Pleural Diseases trials Research Report on Pleural Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Safety and Efficacy of Fibrinolysis in Patients With an Indwelling Pleural Catheter for Multi-loculated Malignant Pleural Effusion. tPA standard dosage, tPA low dosage - Pleural Effusion, Cancer, Lung | Phase 2 | Withdrawn | Yale University | 2018-12-01 | 2020-03-05 | |
| ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment ILX-295501 - Fallopian Tube Cancer, Metastatic Cancer | Phase 2 | Withdrawn | Genzyme, a Sanofi Company | 1999-05-01 | 2018-09-18 |
Carcinoma, Ovarian Epithelial (1) · Fallopian Tube Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Pleural Effusion (1) · Pleural Effusion, Malignant (1)
Neoplasms (2) · Neoplasms by Site (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Adnexal Diseases (1) · Carcinoma (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1)
N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea (1) · Tissue Plasminogen Activator (1)
Genzyme, a Sanofi Company (1) · Yale University (1)
United States (1)
Gayle Cook, RN (1) · Mark Godfrey, MD (1)